Compare Abbott Laboratories (ABT) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Verizon Communications Inc — how do they compare? Abbott Laboratories trades at $111.02 (market cap $187.95B), while Verizon Communications Inc trades at $46.79 (market cap $196.40B). The key difference: Abbott Laboratories and Verizon Communications Inc are close in size by market cap, and Verizon Communications Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| ABT | VZ | |
|---|---|---|
Market Cap | $187.95B | $196.40B |
Sector | Health | Media |
52-Week High | $136.62 | $51.38 |
52-Week Low | $82.57 | $38.40 |
Enterprise Value | $214.96B | $383.10B |
Dividend Yield | 2.32% | 5.99% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Verizon (VZ) trades at $46.77, down 0.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. The company reported Q2 2026 EPS of $1.30, beating estimates, and maintains strong cash flow with $37.14B from operations in 2025. Recent news highlights partnerships, such as with Fi for pet tech integration, and network initiatives amid competitive pressures from SpaceX's Starlink.
Outlook: VZ offers value with a P/E of 12.31 and a 15.63% ROE, supported by stable dividends. Risks include rising debt to $298.5B in 2025 and revenue stagnation. Opportunities lie in fiber expansion and margin improvements, but investor caution is warranted due to competitive threats and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
